Ardelyx announces proposed public offering of common stock
All shares of common stock to be sold in the offering will be offered by Ardelyx. In addition, Ardelyx intends to grant the underwriters of the offering the right for a period of 30 days to purchase up to an additional $12,000,000 of shares of common stock at the public offering price, less underwriting discounts and commissions. In addition, Ardelyx intends to grant the underwriters of the offering the right for a period of 30 days to purchase up to an additional $11,250,000 of shares of common stock at the public FREMONT, Calif., Dec. 4, 2019 /PRNewswire/ — Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with cardiorenal diseases, today announced that it has commenced an underwritten public offering of up to $80,000,000 of shares of its common stock. FREMONT, Calif., Dec. 4, 2019 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with cardiorenal diseases, today announced the pricing of an underwritten public offering of 20,000,000 shares of its common stock at a public offering price of $6.25 per share, before underwriting discounts and commissions, for gross proceeds of $125,000,000.
4 Dec 2019 All shares of common stock to be sold in the offering will be offered by Ardelyx. In addition, Ardelyx intends to grant the underwriters of the
Bloomberg the Company & Its Products Bloomberg Anywhere Remote Login Bloomberg Anywhere Login Bloomberg Terminal Demo Request FREMONT, Calif., Dec. 4, 2019 /PRNewswire/ -- Ardelyx, Inc. (ARDX) , a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with cardiorenal diseases, today announced that it has commenced an underwritten public offering of up to $80,000,000 of shares of its common stock. Tax Planning; Personal Finance; Save for College; Save for Retirement; Invest in Retirement All shares of common stock to be sold in the offering will be offered by Ardelyx. In addition, Ardelyx intends to grant the underwriters of the offering the right for a period of 30 days to purchase up to an additional $12,000,000 of shares of common stock at the public offering price, less underwriting discounts and commissions. In addition, Ardelyx intends to grant the underwriters of the offering the right for a period of 30 days to purchase up to an additional $11,250,000 of shares of common stock at the public FREMONT, Calif., Dec. 4, 2019 /PRNewswire/ — Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with cardiorenal diseases, today announced that it has commenced an underwritten public offering of up to $80,000,000 of shares of its common stock. FREMONT, Calif., Dec. 4, 2019 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with cardiorenal diseases, today announced the pricing of an underwritten public offering of 20,000,000 shares of its common stock at a public offering price of $6.25 per share, before underwriting discounts and commissions, for gross proceeds of $125,000,000.
Ardelyx Announces Proposed Public Offering of Common Stock - Dec. 4, 2019. 12/4/2019. Ardelyx, Inc. announced that it has commenced an underwritten
ARDX Ardelyx, Inc. daily Stock Chart 04:56PM, Ardelyx Announces Proposed Public Offering of Common Stock PR Newswire. 07:06AM, The Daily Biotech Participation from Market Makers and ECNs is strictly voluntary and as a result, these sessions may offer less liquidity and inferior prices. Stock prices may also
Participation from Market Makers and ECNs is strictly voluntary and as a result, these sessions may offer less liquidity and inferior prices. Stock prices may also
Approximate date of commencement of proposed sale to the public: As soon as Includes the offering price of additional shares of common stock that the that we announce or publish from time to time may change as more patient data become since 2009, Ardelyx, Inc., a public specialized biopharmaceutical company, FREMONT, Calif., Dec. 4, 2019 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with cardiorenal diseases, today announced that it has commenced an underwritten public offering of up to $80,000,000 of shares of its common stock.
All shares of common stock to be sold in the offering will be offered by Ardelyx. In addition, Ardelyx intends to grant the underwriters of the offering the right for a period of 30 days to purchase up to an additional $12,000,000 of shares of common stock at the public offering price, less underwriting discounts and commissions.
2020年3月9日 ARDX NASDAQ:ARDX Ardelyx, Inc. 添加自选 · 在APP中查看 Ardelyx Announces Proposed Public Offering of Common Stock. (12-04 19:06). Approximate date of commencement of proposed sale to the public: As soon as Includes the offering price of additional shares of common stock that the that we announce or publish from time to time may change as more patient data become since 2009, Ardelyx, Inc., a public specialized biopharmaceutical company, FREMONT, Calif., Dec. 4, 2019 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with cardiorenal diseases, today announced that it has commenced an underwritten public offering of up to $80,000,000 of shares of its common stock. In addition, Ardelyx intends to grant the underwriters of the offering the right for a period of 30 days to purchase up to an additional $12,000,000 of shares of common stock at the public In addition, Ardelyx intends to grant the underwriters of the offering the right for a period of 30 days to purchase up to an additional $12,000,000 of shares of common stock at the public
Ardelyx: PharmiWeb.com — Ardelyx Announces Presentation at Kidney Week 2019 All — Ardelyx Announces Proposed Public Offering of Common Stock. 4 Dec 2019 Ardelyx (NASDAQ:ARDX) commences an $80M public offering of common stock. Underwriters' over-allotment will be an additional $12M of 3 Feb 2020 today announced that Shane Bowen, Ph.D. has joined the company as Ardelyx Announces Proposed Public Offering of Common Stock. 2020年3月9日 ARDX NASDAQ:ARDX Ardelyx, Inc. 添加自选 · 在APP中查看 Ardelyx Announces Proposed Public Offering of Common Stock. (12-04 19:06). Approximate date of commencement of proposed sale to the public: As soon as Includes the offering price of additional shares of common stock that the that we announce or publish from time to time may change as more patient data become since 2009, Ardelyx, Inc., a public specialized biopharmaceutical company,